1. Home
  2. FR vs NUVL Comparison

FR vs NUVL Comparison

Compare FR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Industrial Realty Trust Inc.

FR

First Industrial Realty Trust Inc.

N/A

Current Price

$58.57

Market Cap

7.7B

Sector

Real Estate

ML Signal

N/A

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

N/A

Current Price

$101.16

Market Cap

7.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FR
NUVL
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
7.1B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
FR
NUVL
Price
$58.57
$101.16
Analyst Decision
Buy
Strong Buy
Analyst Count
11
14
Target Price
$57.64
$134.29
AVG Volume (30 Days)
951.7K
748.2K
Earning Date
02-04-2026
10-30-2025
Dividend Yield
3.07%
N/A
EPS Growth
N/A
N/A
EPS
1.79
N/A
Revenue
$714,032,000.00
N/A
Revenue This Year
$10.87
N/A
Revenue Next Year
$7.46
N/A
P/E Ratio
$32.44
N/A
Revenue Growth
8.93
N/A
52 Week Low
$40.31
$55.54
52 Week High
$59.43
$112.88

Technical Indicators

Market Signals
Indicator
FR
NUVL
Relative Strength Index (RSI) 61.62 45.44
Support Level $57.58 $103.52
Resistance Level $59.43 $107.99
Average True Range (ATR) 1.08 3.11
MACD 0.05 -1.20
Stochastic Oscillator 77.50 2.13

Price Performance

Historical Comparison
FR
NUVL

About FR First Industrial Realty Trust Inc.

First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: